Back to search results

SCI-110 for Tourette Syndrome

This study is testing a new medication called SCI-110 for people with Tourette Syndrome. SCI-110 is a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA). Researchers want to see if SCI-110 is effective, safe, and well-tolerated compared to a placebo (a pill with no active medicine). You might be able to join if you are between 18 and 65 years old, have Tourette Syndrome, and your tic severity score (YGTSS-R) is greater than 14. The main goal is to see how much your tics change after 12 weeks of treatment. The study is currently recruiting 164 participants, but its overall status is unclear.

Study design
This study is interventional and plans to enroll 164 participants. It compares SCI-110 to a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your tic severity will be measured at baseline and 12 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05126888

SCI-110 in the Treatment of Tourette Syndrome

Not Yet Recruiting
PHASE2Ages 18–65InterventionalTreatment
Neurothera Labs Inc.
~164 participants
Updated 2026-04-21 on ClinicalTrials.gov
What's tested:SCI-110Placebo

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)
Measured over At baseline and 12 weeks after start of treatment in both arms.

Conditions

Tourette Syndrome

Explore related trials

Tourette Syndrome

Where it's being run

3 sites across 3 states
Connecticut1
Germany1
Israel1

Study leadership

  • Kirsten R Müller-Vahl, PhD. MD · PRINCIPAL_INVESTIGATOR · Hannover Medical School

Who to contact

Adi Zuloff-Shani, PhD
[email protected]
972-3-7175777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
hysterectomy or uterine agenesis or
≥ 50 years and in postmenopausal state ≥ 1 year or
\< 50 years and in postmenopausal state ≥ 1 year with urine FSH \> 40 IU/l and urine oestrogen \< 30 ng/l, or serum follicle stimulating hormone (FSH) in the post-menopausal range or a negative oestrogen test. 9. Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study

What this trial measures

  • Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)At baseline and 12 weeks after start of treatment in both arms.

    Absolute change from baseline in revised version of YGTSS-R-TTS as a continuous endpoint at week 12 of the respective treatment period. The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.